Qianhai Health Holdings Limited (0911.HK)
HKD 0.21
(0.0%)
HKD 0.21
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -35.6 Million HKD | -146.55% |
| 2022 | 76.48 Million HKD | 376.88% |
| 2021 | 16.03 Million HKD | -64.46% |
| 2020 | 45.12 Million HKD | 38.08% |
| 2019 | 32.68 Million HKD | 988.34% |
| 2018 | 3 Million HKD | -66.34% |
| 2017 | 8.92 Million HKD | 102.24% |
| 2016 | -397.89 Million HKD | -3106.39% |
| 2015 | 13.23 Million HKD | -95.62% |
| 2014 | 302.46 Million HKD | 68.57% |
| 2013 | 179.42 Million HKD | 123.18% |
| 2012 | 80.39 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 21.44 Million HKD | 0.0% |
| 2024 Q1 | 21.44 Million HKD | 173.49% |
| 2023 Q3 | 42.11 Million HKD | 756.03% |
| 2023 Q1 | -59.91 Million HKD | -223.99% |
| 2023 FY | -35.6 Million HKD | -146.55% |
| 2023 Q4 | -29.18 Million HKD | -169.3% |
| 2023 Q2 | -6.41 Million HKD | 89.29% |
| 2022 Q4 | 48.32 Million HKD | 150.95% |
| 2022 Q3 | -94.84 Million HKD | -436.77% |
| 2022 Q1 | 14.08 Million HKD | 360.16% |
| 2022 FY | 76.48 Million HKD | 376.88% |
| 2022 Q2 | 28.16 Million HKD | 100.0% |
| 2021 Q4 | 3.06 Million HKD | 203.03% |
| 2021 FY | 16.03 Million HKD | -64.46% |
| 2021 Q1 | 5.27 Million HKD | -78.55% |
| 2021 Q2 | 12.97 Million HKD | 145.82% |
| 2021 Q3 | -2.97 Million HKD | -122.88% |
| 2020 Q1 | 10.25 Million HKD | -54.04% |
| 2020 Q2 | 20.51 Million HKD | 100.0% |
| 2020 Q3 | 10.55 Million HKD | -48.55% |
| 2020 Q4 | 24.61 Million HKD | 133.16% |
| 2020 FY | 45.12 Million HKD | 38.08% |
| 2019 Q4 | 22.32 Million HKD | 100.0% |
| 2019 Q2 | 10.36 Million HKD | 100.0% |
| 2019 Q1 | 5.18 Million HKD | 155.18% |
| 2019 FY | 32.68 Million HKD | 988.34% |
| 2019 Q3 | 11.15 Million HKD | 7.69% |
| 2018 FY | 3 Million HKD | -66.34% |
| 2018 Q4 | -9.39 Million HKD | 0.0% |
| 2018 Q3 | -9.39 Million HKD | -377.95% |
| 2018 Q2 | 3.37 Million HKD | 0.0% |
| 2018 Q1 | 3.37 Million HKD | 472.63% |
| 2017 Q1 | 3.87 Million HKD | 102.19% |
| 2017 FY | 8.92 Million HKD | 102.24% |
| 2017 Q2 | 3.87 Million HKD | 0.0% |
| 2017 Q4 | 590 Thousand HKD | 0.0% |
| 2017 Q3 | 590 Thousand HKD | -84.76% |
| 2016 Q4 | -176.55 Million HKD | 0.0% |
| 2016 Q3 | -176.55 Million HKD | -901.51% |
| 2016 Q2 | -17.62 Million HKD | 0.0% |
| 2016 Q1 | -17.62 Million HKD | 94.63% |
| 2016 FY | -397.89 Million HKD | -3106.39% |
| 2015 Q2 | 263.83 Million HKD | 0.0% |
| 2015 Q3 | -328.17 Million HKD | -224.39% |
| 2015 FY | 13.23 Million HKD | -95.62% |
| 2015 Q1 | 263.83 Million HKD | 1359.6% |
| 2015 Q4 | -328.17 Million HKD | 0.0% |
| 2014 Q3 | 18.07 Million HKD | -86.43% |
| 2014 Q1 | 133.15 Million HKD | 445.0% |
| 2014 FY | 302.46 Million HKD | 68.57% |
| 2014 Q4 | 18.07 Million HKD | 0.0% |
| 2014 Q2 | 133.15 Million HKD | 0.0% |
| 2013 Q2 | 65.28 Million HKD | 0.0% |
| 2013 Q4 | 24.43 Million HKD | 0.0% |
| 2013 Q3 | 24.43 Million HKD | -62.57% |
| 2013 Q1 | 65.28 Million HKD | 45.53% |
| 2013 FY | 179.42 Million HKD | 123.18% |
| 2012 FY | 80.39 Million HKD | 0.0% |
| 2012 Q4 | 44.85 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | 121.264% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 100.546% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | 223.712% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 109.018% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 106.458% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 102.313% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 107.554% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 116.435% |
| SSY Group Limited | 3.48 Billion HKD | 101.02% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 111.146% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 105.738% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 100.082% |